Novartis AG (NVS) Latest Company News

Jul 2, 2026, 05:57 UTC
The European Commission approved Novartis's Itvisma for the treatment of spinal muscular atrophy in a broad population.
Source:
- finanznachrichten.de
- zacks.com
Jul 1, 2026, 03:32 UTC
Anthropic announced an in-house drug discovery project targeting neglected diseases, entering the healthtech space.
Source:
- techsauce.co
Jun 23, 2026, 19:51 UTC
Novartis AG reported that its experimental drug del-brax, acquired through the Avidity Biosciences deal, showed promise in an early to mid-stage study for facioscapulohumeral muscular dystrophy.
Source:
- ca.finance.yahoo.com
Jun 23, 2026, 19:51 UTC
Novartis AG reported early data from an actinium-based radiopharma drug showing anti-tumor activity in advanced prostate cancer.
Source:
- ca.finance.yahoo.com
Jun 19, 2026, 08:07 UTC
Amgen India appointed Anjali Rao as executive director of human resources.
Source:
- hrkatha.com
- hrkatha.com
Jun 18, 2026, 11:58 UTC
Curium prevailed in a patent dispute brought by Novartis subsidiary Advanced Accelerator Applications in the Delaware U.S. District Court, with all relevant patent claims ruled invalid and not infringed.
Source:
- finanznachrichten.de
Jun 15, 2026, 15:30 UTC
Novartis reports that its drug Rhapsido met the primary goal in a Phase III study for chronic inducible urticaria, supporting new regulatory filings.
Source:
- zacks.com
Jun 11, 2026, 21:41 UTC
Novartis acquired Avidity as part of a $12 billion takeover.
Source:
- reuters.com
Jun 11, 2026, 05:00 UTC
Novartis announced that its del-brax Phase I/II study in FSHD met its primary biomarker endpoint, indicating potential for a first disease-modifying treatment.
Source:

← PreviousPage 2

NVS

The European Commission approved Novartis's Itvisma for the treatment of spinal muscular atrophy in a broad population.

Anthropic announced an in-house drug discovery project targeting neglected diseases, entering the healthtech space.

Novartis AG reported that its experimental drug del-brax, acquired through the Avidity Biosciences deal, showed promise in an early to mid-stage study for facioscapulohumeral muscular dystrophy.

Novartis AG reported early data from an actinium-based radiopharma drug showing anti-tumor activity in advanced prostate cancer.

Amgen India appointed Anjali Rao as executive director of human resources.

Curium prevailed in a patent dispute brought by Novartis subsidiary Advanced Accelerator Applications in the Delaware U.S. District Court, with all relevant patent claims ruled invalid and not infringed.

Novartis reports that its drug Rhapsido met the primary goal in a Phase III study for chronic inducible urticaria, supporting new regulatory filings.

Novartis acquired Avidity as part of a $12 billion takeover.

Novartis announced that its del-brax Phase I/II study in FSHD met its primary biomarker endpoint, indicating potential for a first disease-modifying treatment.